Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 4 (2007), Issue 5 (May)

1. Randomized trial of exercise therapy in women treated for breast cancer.
   J Clin Oncol, 25(13): 1713-21. [Abstract] [Full-text]
2. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy.
   J Natl Cancer Inst, 99(9): 727-37. [Abstract] [Full-text]
3. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.
   J Natl Cancer Inst, 99(9): 694-705. [Abstract] [Full-text]
4. Pharmacodiagnostics and targeted therapies - a rational approach for individualizing medical anticancer therapy in breast cancer.
   Oncologist, 12(4): 397-405. [Abstract] [Full-text]
5. Achieving higher pathological complete response rates in HER-2-positive patients with induction chemotherapy without trastuzumab in operable breast cancer.
   Oncologist, 12(4): 390-6. [Abstract] [Full-text]
6. Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials.
   Oncologist, 12(4): 375-89. [Abstract] [Full-text]
7. Steroid sulfatase: a new target for the endocrine therapy of breast cancer.
   Oncologist, 12(4): 370-4. [Abstract] [Full-text]
8. Artworks, collective experience and claims for social justice: the case of women living with breast cancer.
   Sociol Health Illn, 29(3): 366-90. [Abstract] [Full-text]
9. Identification of novel BRCA large genomic rearrangements in Singapore Asian breast and ovarian patients with cancer.
   Clin Genet, 71(4): 331-42. [Abstract] [Full-text]
10. Barriers to rehabilitation following surgery for primary breast cancer.
    J Surg Oncol, 95(5): 409-18. [Abstract] [Full-text]
11. Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623.
    J Clin Oncol, 25(13): 1677-82. [Abstract] [Full-text]
12. Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis.
    J Clin Oncol, 25(13): 1683-90. [Abstract] [Full-text]
13. Disease-specific genomic analysis: identifying the signature of pathologic biology.
    Bioinformatics, 23(8): 957-65. [Abstract] [Full-text]
14. Immediate dynamic lymphoscintigraphy delivers no additional value to lymphoscintigraphy 3 hr after tracer injection in sentinel lymph node biopsy in breast cancer patients.
    J Surg Oncol, 95(6): 469-75. [Abstract] [Full-text]
15. Chromosome 8 BAC array comparative genomic hybridization and expression analysis identify amplification and overexpression of TRMT12 in breast cancer.
    Genes Chromosomes Cancer, 46(7): 694-707. [Abstract] [Full-text]
16. Women with Saethre-Chotzen syndrome are at increased risk of breast cancer.
    Genes Chromosomes Cancer, 46(7): 656-60. [Abstract] [Full-text]
17. Performance analysis of steady-state harmonic elastography.
    Phys Med Biol, 52(10): 2657-74. [Abstract] [Full-text]
18. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens.
    Clin Cancer Res, 13(9): 2751-7. [Abstract] [Full-text]
19. CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients.
    Clin Cancer Res, 13(9): 2714-21. [Abstract] [Full-text]
20. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    BMC Cancer, 7: 63. [Abstract] [Full-text]
21. 2-DE analysis of a new human cell line EM-G3 derived from breast cancer progenitor cells and comparison with normal mammary epithelial cells.
    Proteomics, 7(9): 1549-59. [Abstract] [Full-text]
22. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers.
    J Clin Invest, 117(5): 1370-80. [Abstract] [Full-text]
23. Age-specific association of steroid hormone pathway gene polymorphisms with breast cancer risk.
    Cancer, 109(10): 1940-8. [Abstract] [Full-text]
24. Does having insurance affect differences in clinical presentation between Hispanic and non-Hispanic white women with breast cancer?
    Cancer, 109(10): 2093-9. [Abstract] [Full-text]
25. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer.
    Cancer, 109(10): 1933-9. [Abstract] [Full-text]
26. The safety of breast-conserving therapy in patients with breast cancer aged < or = 40 years.
    Cancer, 109(10): 1957-64. [Abstract] [Full-text]
27. Randomized controlled trial comparing a low-fat diet with a weight-reduction diet in breast cancer-related lymphedema.
    Cancer, 109(10): 1949-56. [Abstract] [Full-text]
28. Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis.
    Oncogene, 26(20): 2902-13. [Abstract] [Full-text]
29. Functional polymorphisms in the cyclooxygenase 2 (COX-2) gene and risk of breast cancer in a Chinese population.
    J Toxicol Environ Health A, 70(11): 908-15. [Abstract] [Full-text]
30. Metastatic potential of encapsulated (intracystic) papillary carcinoma of the breast: a report of 2 cases with axillary lymph node micrometastases.
    Int J Surg Pathol, 15(2): 143-7. [Abstract] [Full-text]
31. The significance of c-erbB-2 overexpression and p53 expression in patients with axillary lymph node--negative breast cancer: a tissue microarray study.
    Int J Surg Pathol, 15(2): 98-109. [Abstract] [Full-text]
32. Do anxiety, body image, social support and coping strategies predict survival in breast cancer? A ten-year follow-up study.
    Psychosomatics, 48(3): 211-6. [Abstract] [Full-text]
33. Tamoxifen treatment and new-onset depression in breast cancer patients.
    Psychosomatics, 48(3): 205-10. [Abstract] [Full-text]
34. The type I collagen induction of MT1-MMP-mediated MMP-2 activation is repressed by alphaVbeta3 integrin in human breast cancer cells.
    Matrix Biol, 26(4): 291-305. [Abstract] [Full-text]
35. Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance.
    Cancer Res, 67(9): 4459-66. [Abstract] [Full-text]
36. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.
    Cancer Res, 67(9): 4408-17. [Abstract] [Full-text]
37. A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent.
    Cancer Res, 67(9): 4303-10. [Abstract] [Full-text]
38. Regulation of breast cancer response to chemotherapy by fibulin-1.
    Cancer Res, 67(9): 4271-7. [Abstract] [Full-text]
39. Angiopoietin-2 stimulates breast cancer metastasis through the alpha(5)beta(1) integrin-mediated pathway.
    Cancer Res, 67(9): 4254-63. [Abstract] [Full-text]
40. Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells.
    Cancer Res, 67(9): 4199-209. [Abstract] [Full-text]
41. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain.
    Cancer Res, 67(9): 4190-8. [Abstract] [Full-text]
42. Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231.
    Cancer Res, 67(9): 4182-9. [Abstract] [Full-text]
43. Modeling breast cancer-associated c-Src and EGFR overexpression in human MECs: c-Src and EGFR cooperatively promote aberrant three-dimensional acinar structure and invasive behavior.
    Cancer Res, 67(9): 4164-72. [Abstract] [Full-text]
44. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer.
    Cancer Res, 67(9): 4157-63. [Abstract] [Full-text]
45. Identification of novel amplification gene targets in mouse and human breast cancer at a syntenic cluster mapping to mouse ch8A1 and human ch13q34.
    Cancer Res, 67(9): 4104-12. [Abstract] [Full-text]
46. Paradoxes of the EphB4 receptor in cancer.
    Cancer Res, 67(9): 3994-7. [Abstract] [Full-text]
47. Local recurrence of ductal carcinoma in situ after skin-sparing mastectomy.
    J Am Coll Surg, 204(5): 1074-8; discussion 1078-80. [Abstract] [Full-text]
48. Serum biomarkers to differentiate benign and malignant mammographic lesions.
    J Am Coll Surg, 204(5): 1065-71; discussion 1071-3. [Abstract] [Full-text]
49. Correlation of TLK1B in elevation and recurrence in doxorubicin-treated breast cancer patients with high eIF4E overexpression.
    J Am Coll Surg, 204(5): 925-33; discussion 933-4. [Abstract] [Full-text]
50. Managing cardiotoxicity in anthracycline-treated breast cancers.
    Expert Opin Drug Saf, 6(3): 315-21. [Abstract] [Full-text]
51. Akt1 governs breast cancer progression in vivo.
    Proc Natl Acad Sci U S A, 104(18): 7438-43. [Abstract] [Full-text]
52. The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans.
    Proc Natl Acad Sci U S A, 104(18): 7570-5. [Abstract] [Full-text]
53. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1).
    J Biol Chem, 282(19): 14328-36. [Abstract] [Full-text]
54. Loss of HSulf-1 expression enhances autocrine signaling mediated by amphiregulin in breast cancer.
    J Biol Chem, 282(19): 14413-20. [Abstract] [Full-text]
55. Epinephrine protects cancer cells from apoptosis via activation of cAMP-dependent protein kinase and BAD phosphorylation.
    J Biol Chem, 282(19): 14094-100. [Abstract] [Full-text]
56. Cellular automaton simulation examining progenitor hierarchy structure effects on mammary ductal carcinoma in situ.
    J Theor Biol, 246(3): 491-8. [Abstract] [Full-text]
57. High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization.
    Genes Chromosomes Cancer, 46(6): 543-58. [Abstract] [Full-text]
58. p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast.
    J Surg Res, 140(1): 109-14. [Abstract] [Full-text]
59. Relationship of cellular immunity, cytokines and CRP with clinical course in breast cancer patients with endocrine-dependent distant metastases treated with immunotherapy.
    Cancer Lett, 251(2): 330-8. [Abstract] [Full-text]
60. Approaches in modelling long-term survival: an application to breast cancer.
    Stat Med, 26(13): 2666-85. [Abstract] [Full-text]
61. From policy to patients and back: surgical treatment decision making for patients with breast cancer.
    Health Aff (Millwood), 26(3): 761-9. [Abstract] [Full-text]
62. Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis.
    CMAJ, 176(10): 1429-34. [Abstract] [Full-text]
63. Search for DNA of exogenous mouse mammary tumor virus-related virus in human breast cancer samples.
    J Gen Virol, 88: 1806-9. [Abstract] [Full-text]
64. Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice.
    Int J Med Microbiol, 297(3): 151-62. [Abstract] [Full-text]
65. Breast cancer in the elderly.
    J Clin Oncol, 25(14): 1882-90. [Abstract] [Full-text]
66. Adjuvant therapy in the elderly: making the right decision.
    J Clin Oncol, 25(14): 1870-5. [Abstract] [Full-text]
67. Older female cancer patients: importance, causes, and consequences of undertreatment.
    J Clin Oncol, 25(14): 1858-69. [Abstract] [Full-text]
68. Incidence and clinical characteristics of symptomatic choroidal metastasis from breast cancer.
    Acta Ophthalmol Scand, 85(3): 298-302. [Abstract] [Full-text]
69. TPD52 and NFKB1 gene expression levels correlate with G2 chromosomal radiosensitivity in lymphocytes of women with and at risk of hereditary breast cancer.
    Int J Radiat Biol, 83(6): 409-20. [Abstract] [Full-text]
70. Immuno gold nanocages with tailored optical properties for targeted photothermal destruction of cancer cells.
    Nano Lett, 7(5): 1318-22. [Abstract] [Full-text]
71. Resource use and costs associated with different states of breast cancer.
    Int J Technol Assess Health Care, 23(2): 223-31. [Abstract] [Full-text]
72. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
    Expert Rev Anticancer Ther, 7(5): 627-34. [Abstract] [Full-text]
73. Prognostic value of HER2 gene amplification detected by chromogenic in situ hybridization (CISH) in metastatic breast cancer.
    Exp Mol Pathol, 82(3): 262-8. [Abstract] [Full-text]
74. Antitumor activity of edotecarin in breast carcinoma models.
    Cancer Chemother Pharmacol, 60(2): 229-35. [Abstract] [Full-text]
75. Short-term displacement and reproducibility of the breast and nodal targets under active breathing control.
    Int J Radiat Oncol Biol Phys, 68(2): 541-6. [Abstract] [Full-text]
76. Investigating the phenotypes and genotypes of breast cancer in women with African ancestry: the need for more genetic epidemiology.
    Surg Clin North Am, 87(2): 551-68, xii. [Abstract] [Full-text]
77. Radiofrequency, cryoablation, and other modalities for breast cancer ablation.
    Surg Clin North Am, 87(2): 539-50, xii. [Abstract] [Full-text]
78. Locoregional Resection in Stage IV breast cancer: tumor biology, molecular and clinical perspectives.
    Surg Clin North Am, 87(2): 527-38, xi-xii. [Abstract] [Full-text]
79. Postmastectomy radiation therapy: indications and controversies.
    Surg Clin North Am, 87(2): 511-26, xi. [Abstract] [Full-text]
80. Overview of adjuvant systemic therapy in early stage breast cancer.
    Surg Clin North Am, 87(2): 499-509, xi. [Abstract] [Full-text]
81. Integrating partial breast irradiation into surgical practice and clinical trials.
    Surg Clin North Am, 87(2): 485-98, x-xi. [Abstract] [Full-text]
82. Use of ultrasound in breast surgery.
    Surg Clin North Am, 87(2): 469-84, x. [Abstract] [Full-text]
83. Breast reconstruction.
    Surg Clin North Am, 87(2): 453-67, x. [Abstract] [Full-text]
84. Complications in breast surgery.
    Surg Clin North Am, 87(2): 431-51, x. [Abstract] [Full-text]
85. Pregnancy-associated breast cancer: a literature review.
    Surg Clin North Am, 87(2): 417-30, x. [Abstract] [Full-text]
86. Neoadjuvant systemic therapy and the surgical management of breast cancer.
    Surg Clin North Am, 87(2): 399-415, ix. [Abstract] [Full-text]
87. Management of patients with locally advanced breast cancer.
    Surg Clin North Am, 87(2): 379-98, ix. [Abstract] [Full-text]
88. Axillary management after sentinel lymph node biopsy in breast cancer patients.
    Surg Clin North Am, 87(2): 365-77, ix. [Abstract] [Full-text]
89. Lymphatic mapping techniques and sentinel lymph node biopsy in breast cancer.
    Surg Clin North Am, 87(2): 353-64, viii. [Abstract] [Full-text]
90. Ductal carcinoma in situ--current management.
    Surg Clin North Am, 87(2): 333-51, viii. [Abstract] [Full-text]
91. Prophylactic mastectomy.
    Surg Clin North Am, 87(2): 317-31, viii. [Abstract] [Full-text]
92. Breast cancer risk assessment and risk reduction.
    Surg Clin North Am, 87(2): 307-16, vii-viii. [Abstract] [Full-text]
93. Review of breast cancer clinical trials conducted by the National Surgical Adjuvant Breast Project.
    Surg Clin North Am, 87(2): 279-305, vii. [Abstract] [Full-text]
94. Cancer risks for Australian women with a BRCA1 or a BRCA2 mutation.
    ANZ J Surg, 77(5): 314-9. [Abstract] [Full-text]
95. LPA2 (EDG4) mediates Rho-dependent chemotaxis with lower efficacy than LPA1 (EDG2) in breast carcinoma cells.
    Am J Physiol Cell Physiol, 292(5): C1927-33. [Abstract] [Full-text]
96. 90Y radioembolization of metastatic breast cancer to the liver: toxicity, imaging response, survival.
    J Vasc Interv Radiol, 18(5): 621-8. [Abstract] [Full-text]
97. Cone beam computed tomography guidance for setup of patients receiving accelerated partial breast irradiation.
    Int J Radiat Oncol Biol Phys, 68(2): 547-54. [Abstract] [Full-text]
98. Predictors of cosmetic outcome following MammoSite breast brachytherapy: a single-institution experience of 100 patients with two years of follow-up.
    Int J Radiat Oncol Biol Phys, 68(2): 354-8. [Abstract] [Full-text]
99. Risk of second malignancies after adjuvant radiotherapy for breast cancer: a large-scale, single-institution review.
    Int J Radiat Oncol Biol Phys, 68(2): 359-63. [Abstract] [Full-text]
100. Four-week course of radiation for breast cancer using hypofractionated intensity modulated radiation therapy with an incorporated boost.
     Int J Radiat Oncol Biol Phys, 68(2): 347-53. [Abstract] [Full-text]
101. Dysregulation of HER2/HER3 signaling axis in Epstein-Barr virus-infected breast carcinoma cells.
     J Virol, 81(11): 5705-13. [Abstract] [Full-text]
102. The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.
     J Biol Chem, 282(20): 15271-83. [Abstract] [Full-text]
103. Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer.
     Int J Radiat Oncol Biol Phys, 68(2): 334-40. [Abstract] [Full-text]
104. Vascular proliferations of the skin after radiation therapy for breast cancer: clinicopathologic analysis of a series in favor of a benign process: a study from the French Sarcoma Group.
     Cancer, 109(8): 1584-98. [Abstract] [Full-text]
105. Shedding of syndecan-1 by stromal fibroblasts stimulates human breast cancer cell proliferation via FGF2 activation.
     J Biol Chem, 282(20): 14906-15. [Abstract] [Full-text]
106. Male breast cancer in the veterans affairs population: a comparative analysis.
     Cancer, 109(8): 1471-7. [Abstract] [Full-text]
107. Breast cancer patients with 10 or more involved axillary lymph nodes treated by multimodality therapy: influence of clinical presentation on outcome.
     Int J Radiat Oncol Biol Phys, 68(2): 364-9. [Abstract] [Full-text]
108. Long-term efficacy and patterns of failure after accelerated partial breast irradiation: a molecular assay-based clonality evaluation.
     Int J Radiat Oncol Biol Phys, 68(2): 341-6. [Abstract] [Full-text]
109. eEF1A2 activates Akt and stimulates Akt-dependent actin remodeling, invasion and migration.
     Oncogene, 26(21): 3027-40. [Abstract] [Full-text]
110. Frequent epigenetic inactivation of cystatin M in breast carcinoma.
     Oncogene, 26(21): 3089-94. [Abstract] [Full-text]
111. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients.
     Pharmacogenet Genomics, 17(6): 431-45. [Abstract] [Full-text]
112. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients.
     Br J Cancer, 96(10): 1504-13. [Abstract] [Full-text]
113. Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer.
     Br J Cancer, 96(10): 1526-31. [Abstract] [Full-text]
114. Combination treatment with Grb7 peptide and Doxorubicin or Trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells.
     Br J Cancer, 96(10): 1520-5. [Abstract] [Full-text]
115. Impact of an increase in grading categories and double reporting on the reliability of breast cancer grade.
     APMIS, 115(4): 360-6. [Abstract] [Full-text]
116. Nectin-4 is a new histological and serological tumor associated marker for breast cancer.
     BMC Cancer, 7: 73. [Abstract] [Full-text]
117. Radiotherapy waiting times for women with breast cancer: a population-based cohort study.
     BMC Cancer, 7: 71. [Abstract] [Full-text]
118. High-level JAG1 mRNA and protein predict poor outcome in breast cancer.
     Mod Pathol, 20(6): 685-93. [Abstract] [Full-text]
119. Genomic instability within tumor stroma and clinicopathological characteristics of sporadic primary invasive breast carcinoma.
     JAMA, 297(19): 2103-11. [Abstract] [Full-text]
120. Fine-needle aspiration cytology of medullary breast carcinoma: report of two cases and review of the literature with emphasis on differential diagnosis.
     Diagn Cytopathol, 35(6): 313-8. [Abstract] [Full-text]
121. Cytological diagnosis of collagenous spherulosis of breast associated with fibroadenoma: report of a case with review of literature.
     Diagn Cytopathol, 35(6): 366-9. [Abstract] [Full-text]
122. The effects of antibody clone and pretreatment method on the results of HER2 immunostaining in cytologic samples of metastatic breast cancer: A query and a review of the literature.
     Diagn Cytopathol, 35(6): 319-28. [Abstract] [Full-text]
123. Tamoxifen-induced rapid death of MCF-7 breast cancer cells is mediated via extracellularly signal-regulated kinase signaling and can be abrogated by estrogen.
     Endocrinology, 148(6): 2764-77. [Abstract] [Full-text]
124. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion.
     Oncogene, 26(23): 3329-37. [Abstract] [Full-text]
125. Breast cancer screening for Korean women must consider traditional risks as well as two genetic risk factors: genetic polymorphisms and inheritable gene mutations.
     Cancer Nurs, 30(3): 213-22. [Abstract] [Full-text]
126. Breast cancer diagnosis and its treatment affecting the self: a meta-synthesis.
     Cancer Nurs, 30(3): 194-202; quiz 203-4. [Abstract] [Full-text]
127. Reliability and validity of the Champion's Health Belief Model Scale among Lithuanian women.
     Cancer Nurs, 30(3): E20-8. [Abstract] [Full-text]
128. Individual psychosocial support for breast cancer patients: a randomized study of nurse versus psychologist interventions and standard care.
     Cancer Nurs, 30(3): E10-9. [Abstract] [Full-text]
129. Novel estrogen receptor-alpha binding sites and estradiol target genes identified by chromatin immunoprecipitation cloning in breast cancer.
     Cancer Res, 67(10): 5017-24. [Abstract] [Full-text]
130. Survivin, a member of the inhibitor of apoptosis family, is induced by photodynamic therapy and is a target for improving treatment response.
     Cancer Res, 67(10): 4989-95. [Abstract] [Full-text]
131. Rap1 integrates tissue polarity, lumen formation, and tumorigenic potential in human breast epithelial cells.
     Cancer Res, 67(10): 4759-66. [Abstract] [Full-text]
132. Mitochondrial genetic background modifies breast cancer risk.
     Cancer Res, 67(10): 4687-94. [Abstract] [Full-text]
133. Silencing of cyclooxygenase-2 inhibits metastasis and delays tumor onset of poorly differentiated metastatic breast cancer cells.
     Mol Cancer Res, 5(5): 435-42. [Abstract] [Full-text]
134. Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer.
     Cancer Res, 67(10): 4564-71. [Abstract] [Full-text]
135. Trends in mammography and clinical breast examination: a population-based study.
     J Surg Res, 140(2): 214-9. [Abstract] [Full-text]
136. Immunohistochemical detection of antiapoptotic protein X-linked inhibitor of apoptosis in mammary carcinoma.
     Hum Pathol, 38(6): 864-70. [Abstract] [Full-text]
137. Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype.
     Hum Pathol, 38(6): 830-41. [Abstract] [Full-text]
138. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.
     J Clin Oncol, 25(15): 2127-32. [Abstract] [Full-text]
139. Impact of a peer-delivered telephone intervention for women experiencing a breast cancer recurrence.
     J Clin Oncol, 25(15): 2093-9. [Abstract] [Full-text]
140. Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes.
     J Clin Oncol, 25(15): 2027-34. [Abstract] [Full-text]
141. Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14.
     J Clin Oncol, 25(15): 2012-8. [Abstract] [Full-text]
142. User-centered research on breast cancer patient needs and preferences of an Internet-based clinical trial matching system.
     J Med Internet Res, 9(2): e13. [Abstract] [Full-text]
143. Accuracy of contrast-enhanced breast ultrasound for pre-operative tumor size assessment in patients diagnosed with invasive ductal carcinoma of the breast.
     Cancer Imaging, 7: 63-8. [Abstract] [Full-text]
144. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.
     Lancet, 369(9574): 1711-23. [Abstract] [Full-text]
145. Brain metastases: old problem, new strategies.
     Hematol Oncol Clin North Am, 21(2): 369-88. [Abstract] [Full-text]
146. Bisphosphonates for breast cancer: questions answered, questions remaining.
     Hematol Oncol Clin North Am, 21(2): 341-67. [Abstract] [Full-text]
147. Emerging targeted therapies for breast cancer.
     Hematol Oncol Clin North Am, 21(2): 321-40. [Abstract] [Full-text]
148. Bevacizumab for advanced breast cancer.
     Hematol Oncol Clin North Am, 21(2): 303-19. [Abstract] [Full-text]
149. HER2-positive advanced breast cancer.
     Hematol Oncol Clin North Am, 21(2): 293-302. [Abstract] [Full-text]
150. Hormonal therapy for advanced breast cancer.
     Hematol Oncol Clin North Am, 21(2): 273-91. [Abstract] [Full-text]
151. Chemotherapy for metastatic breast cancer.
     Hematol Oncol Clin North Am, 21(2): 257-72. [Abstract] [Full-text]
152. Trastuzumab (herceptin) for early-stage breast cancer.
     Hematol Oncol Clin North Am, 21(2): 239-56. [Abstract] [Full-text]
153. Adjuvant endocrine treatment of early breast cancer.
     Hematol Oncol Clin North Am, 21(2): 223-38. [Abstract] [Full-text]
154. Adjuvant chemotherapy for early-stage breast cancer.
     Hematol Oncol Clin North Am, 21(2): 207-22. [Abstract] [Full-text]
155. A pathologist's perspective on emerging genomic tests for breast cancer.
     Semin Oncol, 34(2): S4-9. [Abstract] [Full-text]
156. Biomarker studies and other difficult inferential problems: statistical caveats.
     Semin Oncol, 34(2): S17-22. [Abstract] [Full-text]
157. New generation of molecular prognostic and predictive tests for breast cancer.
     Semin Oncol, 34(2): S10-6. [Abstract] [Full-text]
158. Immediate reconstruction using inframammary adipofascial flap of the anterior rectus sheath after partial mastectomy.
     Am J Surg, 193(6): 789-91. [Abstract] [Full-text]
159. Fear of missing a lesion: use of simulated breast models to decrease student anxiety when learning clinical breast examinations.
     Am J Surg, 193(6): 766-70. [Abstract] [Full-text]
160. Comparison of two models for the prediction of nonsentinel node metastases in breast cancer.
     Am J Surg, 193(6): 686-92. [Abstract] [Full-text]
161. The potentiation of curcumin on insulin-like growth factor-1 action in MCF-7 human breast carcinoma cells.
     Life Sci, 80(23): 2161-9. [Abstract] [Full-text]
162. Municipal distribution of breast cancer mortality among women in Spain.
     BMC Cancer, 7: 78. [Abstract] [Full-text]
163. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.
     J Clin Oncol, 25(15): 2006-11. [Abstract] [Full-text]
164. Comprehensive annotation of bidirectional promoters identifies co-regulation among breast and ovarian cancer genes.
     PLoS Comput Biol, 3(4): e72. [Abstract] [Full-text]
165. The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer.
     J Clin Oncol, 25(15): 2019-26. [Abstract] [Full-text]
166. Favorable pregnancy outcome following Trastuzumab (Herceptin) use during pregnancy--Case report and updated literature review.
     Reprod Toxicol, 23(4): 611-3. [Abstract] [Full-text]
167. The results of a structured diagnostic pathway designed to minimise the chance of breast cancer misdiagnosis.
     Eur J Surg Oncol, 33(5): 551-5. [Abstract] [Full-text]
168. Label-free biosensor: a novel phage-modified Light Addressable Potentiometric Sensor system for cancer cell monitoring.
     Biosens Bioelectron, 22(12): 3261-6. [Abstract] [Full-text]
169. The role of surgery in the management of solitary pulmonary nodule in breast cancer patients.
     Eur J Surg Oncol, 33(5): 546-50. [Abstract] [Full-text]
170. Polymorphisms of short tandem repeat of genes and breast cancer susceptibility.
     Eur J Surg Oncol, 33(5): 529-34. [Abstract] [Full-text]
171. Breast reconstruction following mastectomy for invasive breast cancer by free flaps from the abdomen is oncologically safe.
     Eur J Surg Oncol, 33(5): 541-5. [Abstract] [Full-text]
172. Fine-needle aspiration cytology of metaplastic carcinoma of the breast.
     J Clin Pathol, 60(5): 529-33. [Abstract] [Full-text]
173. Evidence-based target recall rates for screening mammography.
     Radiology, 243(3): 681-9. [Abstract] [Full-text]
174. Recent advances in the medical management of breast cancer: highlights from the 29th San Antonio Breast Cancer Conference San Antonio, TX, USA, 14-17 December 2007.
     Expert Opin Pharmacother, 8(8): 1179-88. [Abstract] [Full-text]
175. Expression of the protein phosphatase 1 inhibitor KEPI is downregulated in breast cancer cell lines and tissues and involved in the regulation of the tumor suppressor EGR1 via the MEK-ERK pathway.
     Biol Chem, 388(5): 489-95. [Abstract] [Full-text]
176. Mid-region parathyroid hormone-related protein (PTHrP) and gene expression of MDA-MB231 breast cancer cells.
     Biol Chem, 388(5): 457-65. [Abstract] [Full-text]
177. Impact of PET/CT in comparison with same day contrast enhanced CT in breast cancer management.
     Clin Nucl Med, 32(6): 429-34. [Abstract] [Full-text]
178. Are 3 sentinel nodes sufficient?
     Arch Surg, 142(5): 456-9; discussion 459-60. [Abstract] [Full-text]
179. Evaluating the impact of preoperative breast magnetic resonance imaging on the surgical management of newly diagnosed breast cancers.
     Arch Surg, 142(5): 441-5; discussion 445-7. [Abstract] [Full-text]
180. BimL involvement in Bax activation during UV irradiation-induced apoptosis.
     Biochem Biophys Res Commun, 358(2): 559-65. [Abstract] [Full-text]
181. Anaplastic lymphoma kinase is expressed in different subtypes of human breast cancer.
     Biochem Biophys Res Commun, 358(2): 399-403. [Abstract] [Full-text]
182. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer.
     Clin Chem, 53(6): 1084-91. [Abstract] [Full-text]
183. Contrast-enhanced MR mammography for evaluation of the contralateral breast in patients with diagnosed unilateral breast cancer or high-risk lesions.
     Radiology, 243(3): 670-80. [Abstract] [Full-text]
184. High dose chemotherapy for poor prognosis breast cancer: systematic review and meta-analysis.
     Cancer Treat Rev, 33(4): 325-37. [Abstract] [Full-text]
185. Psychological factors predict patient satisfaction with postmastectomy breast reconstruction.
     Plast Reconstr Surg, 119(7): 2008-15; discussion 2016-7. [Abstract] [Full-text]
186. Assessing the risk of bone fracture among postmenopausal women who are receiving adjuvant hormonal therapy for breast cancer.
     Curr Med Res Opin, 23(5): 1045-51. [Abstract] [Full-text]
187. Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer.
     Mol Pharmacol, 71(6): 1525-34. [Abstract] [Full-text]
188. The cofilin pathway in breast cancer invasion and metastasis.
     Nat Rev Cancer, 7(6): 429-40. [Abstract] [Full-text]
189. Breast, colorectal, and skin cancer screening practices and family history of cancer in U.S. women.
     J Womens Health (Larchmt), 16(4): 526-34. [Abstract] [Full-text]
190. The development of an arm activity survey for breast cancer survivors using the Protection Motivation Theory.
     BMC Cancer, 7: 75. [Abstract] [Full-text]
191. Effect of mammographic service screening on stage at presentation of breast cancers in Sweden.
     Cancer, 109(11): 2205-12. [Abstract] [Full-text]
192. Pilot study of regional, hepatic intra-arterial paclitaxel in patients with breast carcinoma metastatic to the liver.
     Cancer, 109(11): 2190-6. [Abstract] [Full-text]
193. Antiestrogenic effect of 20S-protopanaxadiol and its synergy with tamoxifen on breast cancer cells.
     Cancer, 109(11): 2374-82. [Abstract] [Full-text]
194. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
     Cancer, 109(11): 2197-204. [Abstract] [Full-text]
195. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.
     Cancer, 109(9): 1721-8. [Abstract] [Full-text]
196. Expression patterns of the ATM gene in mammary tissues and their associations with breast cancer survival.
     Cancer, 109(9): 1729-35. [Abstract] [Full-text]
197. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study.
     Cancer, 109(9): 1905-13. [Abstract] [Full-text]
198. Diagnostic accuracy of methods for the detection of BRCA1 and BRCA2 mutations: a systematic review.
     Eur J Hum Genet, 15(6): 619-27. [Abstract] [Full-text]
199. Protective roles of quinone reductase and tamoxifen against estrogen-induced mammary tumorigenesis.
     Oncogene, 26(24): 3587-90. [Abstract] [Full-text]
200. Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review.
     Int J Cancer, 121(2): 225-31. [Abstract] [Full-text]
201. Medical radiation exposure and breast cancer risk: findings from the Breast Cancer Family Registry.
     Int J Cancer, 121(2): 386-94. [Abstract] [Full-text]
202. Breast cancer risk and erythrocyte compositions of n-3 highly unsaturated fatty acids in Japanese.
     Int J Cancer, 121(2): 377-85. [Abstract] [Full-text]
203. Cell membrane reactivity of MIB-1 antibody to Ki67 in human tumors: fact or artifact?
     Appl Immunohistochem Mol Morphol, 15(2): 220-3. [Abstract] [Full-text]
204. Estrogen receptor antibody incubation time and extent of immunoreactivity in invasive carcinoma of the breast: the importance of optimizing antibody avidity.
     Appl Immunohistochem Mol Morphol, 15(2): 203-7. [Abstract] [Full-text]
205. Immunohistochemical staining of papillary breast lesions.
     Appl Immunohistochem Mol Morphol, 15(2): 145-53. [Abstract] [Full-text]
206. Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways.
     Mol Endocrinol, 21(6): 1335-58. [Abstract] [Full-text]
207. Full-thickness chest wall resection for recurrent breast phyllodes tumor.
     Ann Thorac Surg, 83(6): 2196-7. [Abstract] [Full-text]
208. Tamoxifen and its main metabolites serum and tissue concentrations in breast cancer women.
     Ther Drug Monit, 29(3): 349-52. [Abstract] [Full-text]
209. Quality of life assessment in women with breast cancer: benefits, acceptability and utilization.
     Health Qual Life Outcomes, 5: 24. [Abstract] [Full-text]
210. The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells.
     J Biol Chem, 282(22): 16667-80. [Abstract] [Full-text]
211. Routine screening mammography in women older than 74 years: a review of the available data.
     Maturitas, 57(2): 109-19. [Abstract] [Full-text]
212. Recent increase of breast cancer incidence among women under the age of forty.
     Br J Cancer, 96(11): 1743-6. [Abstract] [Full-text]
213. Intakes of calcium and vitamin D and breast cancer risk in women.
     Arch Intern Med, 167(10): 1050-9. [Abstract] [Full-text]
214. Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial.
     Br J Cancer, 96(11): 1633-8. [Abstract] [Full-text]
215. Alternative methods of follow up in breast cancer: a systematic review of the literature.
     Br J Cancer, 96(11): 1625-32. [Abstract] [Full-text]
216. Estimates of heritable and environmental components of familial breast cancer using family history information.
     Br J Cancer, 96(11): 1740-2. [Abstract] [Full-text]
217. Urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG) and genetic polymorphisms in breast cancer patients.
     Mutat Res, 631(1): 62-8. [Abstract] [Full-text]
218. Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells.
     BMC Cancer, 7: 80. [Abstract] [Full-text]
219. Effective treatment of human breast tumor in a mouse xenograft model with herpes simplex virus type 1 specifying the NV1020 genomic deletion and the gBsyn3 syncytial mutation enabling high viral replication and spread in breast cancer cells.
     Hum Gene Ther, 18(5): 457-73. [Abstract] [Full-text]
220. Phase I-II trial of prone accelerated intensity modulated radiation therapy to the breast to optimally spare normal tissue.
     J Clin Oncol, 25(16): 2236-42. [Abstract] [Full-text]
221. Epigenetic silencing of the candidate tumor suppressor gene PROX1 in sporadic breast cancer.
     Int J Cancer, 121(3): 547-54. [Abstract] [Full-text]
222. Comparison of gene expression data from human and mouse breast cancers: identification of a conserved breast tumor gene set.
     Int J Cancer, 121(3): 683-8. [Abstract] [Full-text]
223. Signs of proinflammatory/genotoxic switch (adipogenotoxicosis) in mammary fat of breast cancer patients: role of menopausal status, estrogens and hyperglycemia.
     Int J Cancer, 121(3): 514-9. [Abstract] [Full-text]
224. Hormone replacement therapy and breast cancer in former users of oral contraceptives--The Norwegian Women and Cancer study.
     Int J Cancer, 121(3): 645-8. [Abstract] [Full-text]
225. Incidence of breast cancer among postmenopausal, hypertensive women.
     Int J Cancer, 121(3): 641-4. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.